Sign In
Buy ALEC
$1.78
-0.175 (-8.97%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., July 21, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company.
Should You Take Comfort From Insider Transactions At Alector, Inc. (NASDAQ:ALEC)?
11:31am, Wednesday, 15'th Jul 2020
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Hedge Funds Keep Buying Alector, Inc. (ALEC)
11:16pm, Sunday, 28'th Jun 2020
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma
Chronic treatment enhanced neuroprotective microglia, reduced neuronal damage, tempered microglial inflammatory response and contained toxic beta amyloid plaques in a mouse model of Alzheimer’s dise
Women are more prone to Alzheimer’s disease 'due to the menopause', study warns
08:00pm, Wednesday, 24'th Jun 2020
Scientists from Weill Cornell Graduate School of Medical Sciences in New York have revealed that women are more prone to Alzheimer’s disease than men due to the menopause
Insider Selling: Alector Inc (NASDAQ:ALEC) Insider Sells $296,100.00 in Stock
05:54am, Saturday, 20'th Jun 2020
Alector Inc (NASDAQ:ALEC) insider Robert Paul sold 10,000 shares of Alector stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $29.61, for a total transaction
NortonLifeLock and Bancorp See Activist Actions
11:00pm, Friday, 12'th Jun 2020
Starboard Value sold 10.9 million NortonLifeLock shares to trim its stake in the cybersecurity firm to 5.6%. Castle Creek raised its stake in fintech firm Bancorp to 6.3%.
Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
08:01pm, Wednesday, 03'rd Jun 2020
SOUTH SAN FRANCISCO, Calif., June 03, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of.
Analysts Have Made A Financial Statement On Alector, Inc.'s (NASDAQ:ALEC) First-Quarter Report
12:05pm, Saturday, 16'th May 2020
The analysts might have been a bit too bullish on Alector, Inc. (NASDAQ:ALEC), given that the company fell short of...
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
01:25pm, Wednesday, 13'th May 2020
Alector (ALEC) delivered earnings and revenue surprises of -10.42% and -32.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alector Reports 2020 First Quarter Financial Results and Business Highlights
12:00pm, Wednesday, 13'th May 2020
“Our COVID-19 task force and the entire Alector team continues to focus on initiating a pivotal Phase 3 study of AL001 in FTD-GRN patients and a Phase 2 study of AL002 in Alzheimer’s disease patie
Alector to Present at the Bank of America Securities Virtual Health Care Conference
12:30pm, Thursday, 07'th May 2020
SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz.
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30% (NEWS-PORTAL)
12:20pm, Monday, 04'th May 2020
Times are changing on Wall Street. The COVID-19 pandemic and the havoc it’s wreaking have induced levels of return dispersion unlike anything witnessed since the Great Depression, but this isn’t n
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30%
11:00am, Sunday, 03'rd May 2020
Times are changing on Wall Street. The COVID-19 pandemic and the havoc it’s wreaking have induced levels of return dispersion unlike anything witnessed since the Great Depression, but this isn’t n
Alector Inc (NASDAQ:ALEC) Given Average Recommendation of "Buy" by Analysts
05:36am, Saturday, 02'nd May 2020
Shares of Alector Inc (NASDAQ:ALEC) have received a consensus rating of “Buy” from the ten research firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the
